Eli Lilly is close to launching its own oral anti-obesity medicine, orforglipron.
This new therapy could be better than oral Wegovy and allow Lilly to remain the weight-loss leader.
In January, Novo Nordisk (NYSE: NVO) broke new ground in the weight-loss market by launching an oral version of its famous anti-obesity drug, Wegovy. It’s the first oral GLP-1 approved for chronic weight management, and Novo Nordisk hopes it will help it regain market share in this area.
While oral Wegovy has so far had a successful launch, another oral GLP-1 could hit the market this year and eclipse it. Here’s what investors need to know.
Will AI create the world’s first trillionaire? Our team just released a report on the one little-known company, called an “Indispensable Monopoly” providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
Last year, Eli Lilly (NYSE: LLY) posted strong phase 3 results for orforglipron, an oral GLP-1 medicine, in weight management and in helping type 2 diabetes patients lower their A1C levels. Lilly has submitted the drug to regulatory authorities for approval, which could come down during the second quarter, so it’s gearing up to launch orforglipron. The company already has about $1.5 billion in inventory, and management said it would be ready to roll it out about a week after approval.
Though Eli Lilly is already dominating the weight loss market thanks to Zepbound, orforglipron should help cement its lead. Here are three reasons why.
First, as Lilly noted, oral Wegovy is actually expanding the market, not just capturing existing weight-loss patients who were previously taking subcutaneous medicines. Orforglipron, then, could have a similar trajectory, helping the company attract newer patients who were hesitant to start treatment because they didn’t like needles, or because the storage requirements of injections were too daunting.
Second, orforglipron does not require any food or beverage intake restrictions. By contrast, oral Wegovy must be taken first thing in the morning on an empty stomach, a (seemingly) small detail that could help the newer drug attract a meaningful number of patients.
Third — and perhaps most importantly — while oral Wegovy is indicated only for weight loss, orforglipron could be approved for diabetes as well. Its phase 3 performance in helping type 2 diabetes patients shed excess weight was particularly strong; it also performed better than Rybelsus — another oral GLP-1 marketed by Novo Nordisk — in lowering patients’ A1C levels.
This strongly suggests that orforglipron could enjoy stronger adoption among physicians and patients, helping Eli Lilly dominate the oral weight loss market.
Eli Lilly has crushed the market over the past five years, but its stock can still deliver excellent returns from here on out. The drugmaker’s work in this therapeutic area is a key reason. Analysts continue to project that the anti-obesity space will grow rapidly in the coming years. And Eli Lilly not only has established itself as a leader, but also boasts pipeline candidates that put those of its competitors to shame.
Orforglipron is just one of them. Eli Lilly’s retatrutide, a medicine that mimics the action of three gut hormones (no such “triple agonist” has yet been approved), posted outstanding phase 3 results last year.
Lilly should remain the leader in this field for the foreseeable future, and the company is using its success in the area to expand and diversify its pipeline. The healthcare giant is well-positioned to deliver strong financial results and above-average market returns.
Before you buy stock in Eli Lilly, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $522,791!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,132,678!*
Now, it’s worth noting Stock Advisor’s total average return is 952% — a market-crushing outperformance compared to 191% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 11, 2026.
Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
